Frontline therapy with Tevimbra plus chemotherapy confirmed promising efficacy and manageable security in superior gastric/GEJ most cancers.
Amongst sufferers with superior, HER2-negative, mismatch repair-proficient gastric and gastroesophageal junction adenocarcinoma, frontline therapy with Tevimbra (tislelizumab) plus irinotecan, paclitaxel, oxaliplatin and 5-flourouracil/leucovorin (POFI) was proven to be each lively and have a manageable security profile, trial outcomes have proven.
Knowledge from the section 1/2 SYLT-023 trial had been introduced on the 2025 Gastrointestinal Cancers Symposium.
On the information cutoff date of Sept. 18, 2024, the confirmed goal response (ORR) charge in sufferers with measurable illness (13 sufferers) was 100% (full response [CR], 6.7%; partial response, 80%). Of the 2 sufferers with non-measurable illness, one had CR (6.7%) and the second had non-CR/non-progressive illness (6.7%). Within the complete sufferers, the ORR was 93.5% (14 sufferers) and the illness management charge (DCR) was 100% (15 sufferers).
The median progression-free survival (PFS) was 10.51 months, and the median total survival (OS) was 14.75 months. The median length of response was 7.39 months.
“[Tevimbra] plus POFI was nicely tolerated and confirmed preliminary antitumor exercise in [patients with] superior gastric most cancers, [and] a section 2 examine on the beneficial section 2 dose [RP2D] is ongoing,” lead examine writer Dr. Liyu Su, of Fujian Most cancers Hospital and Fujian Medical College Most cancers Hospital, Fuzhou, Fujian, China and coauthors, wrote within the poster.
Glossary:
Anemia: low rely of wholesome pink blood cells.
Full response: disappearance of most cancers.
Illness management charge: sufferers whose illness shrunk, stabilized or disappeared from therapy.
Length of response: how lengthy a affected person responds to therapy.
ECOG efficiency standing: a scoring system for a affected person’s potential to finish every day duties, with a decrease rating that means better independence.
Elevated alkaline phosphatase: a possible indication of bone or liver illness.
Hypokalemia: low ranges of potassium.
Leukocytopenia: low white blood cell rely.
Goal response charge: sufferers who responded partially or fully to therapy.
General survival: how lengthy a affected person lives, no matter illness standing.
Partial response: a lower within the extent of illness within the physique as a consequence of therapy.
PD-L1 mixed optimistic rating: a measurement of PD-L1 optimistic cells within the physique.
Development-free survival: the time a affected person lives with out their illness spreading or worsening.
Gastric most cancers is the fifth commonest most cancers globally, with a excessive incidence in China. Regardless of the exercise of Tevimbra plus platinum and fluoropyrimidine-based chemotherapy in sufferers with superior gastric most cancers, evidenced within the section 3 RATIONALE-305 trial, outcomes stay poor.
Nevertheless, stronger cytotoxic brokers may potentiate larger ranges of immunogenic cell demise, main to higher T-cell activation and subsequent exercise of checkpoint inhibition. This, coupled with information exhibiting improved outcomes with paclitaxel plus modified FOLFOX versus FOLFOX and antitumor exercise with irinotecan in superior gastric most cancers, served as the premise for the current examine.
The examine enrolled sufferers between the ages of 18 and 70 years who had obtained a histologically or cytologically confirmed analysis of superior unresectable adenocarcinoma of the gastric or gastroesophageal junction. Eligibility standards required that sufferers have an evaluable lesion, an ECOG efficiency standing of 0 or 1, ample organ operate and a life expectancy of at the very least three months. Prior chemotherapy or radiation remedy was not allowed aside from chemotherapy obtained within the (neo)adjuvant setting that had been accomplished greater than six months previous to relapse.
In any respect dose ranges, sufferers obtained Tevimbra at 200 milligrams (mg) each two weeks (Q2W), oxaliplatin at 85 mg per sq. meter (mg/m2) Q2W, levoleucovorin at 200 mg/m2 Q2W, and 5-FU at 2400 mg/m2 over the course of 46 hours Q2W. These in dose degree 1 (three sufferers) obtained irinotecan at 135 mg/m2 Q2W and paclitaxel at 45 mg/m2 Q2W; these in dose degree 2 (three sufferers), obtained irinotecan at 150 mg/m2 Q2W and paclitaxel at 45 mg/m2 Q2W; these in dose degree 3 (three sufferers), obtained irinotecan at 135 mg/m2 Q2W and paclitaxel at 67.5 mg/m2 Q2W; and people in dose degree 4 (six sufferers) obtained irinotecan at 135 mg/m2 Q2W and paclitaxel at 90 mg/m2 Q2W.
Among the many 15 complete sufferers, the median age was 65 years. Nearly all of sufferers had been male (80%), 65 years of age or older (60%), and had an ECOG efficiency standing of 0 (80%) with a major tumor positioned within the gastric tract (86.7%). The first histologic sort was undifferentiated (73.3%), and the first tumor was current usually (93.3%). Roughly one-third of sufferers (66.7%) had at the very least two metastatic organs concerned, with websites together with the lymph nodes (86.7%), liver (33.3%), peritoneum (20%), lung (6.7%) and others (13.3%). Most sufferers didn’t obtain prior chemotherapy as required by the eligibility standards (80%). PD-L1 mixed optimistic rating (CPS) was 0 in 60% of sufferers, at the very least 1 in 40% and 5 or larger in 33.3%.
Further efficacy outcomes damaged down by CPS indicated that the median PFS in sufferers with a rating under 1 was 11.14 months versus 8.76 months in these with a rating of 1 or larger. The median OS in sufferers with scores under 1 and 1 or larger, respectively, was 12.29 months versus 20.88 months.
Relating to security, one dose-limiting toxicity of grade 4 neutropenia occurred inside 28 days in dose degree 4, however the MTD was not reached. The RP2D was decided to be 135 mg of irinotecan each two weeks, 90 mg of paclitaxel each two weeks, 85 mg/m2 of oxaliplatin, 200 mg/m2 of leucovorin, 2400 mg/m2 of 5-flourouracil for 46 hours each two weeks, and 200 mg of Tevimbra each two weeks.
All sufferers skilled treatment-related unwanted effects; 73.3% of sufferers skilled grade 3 (extreme) or larger occasions. Remedy-related unwanted effects included anemia (all grade, 100%; grade 3 or larger, 26.7%, respectively) leukocytopenia (86.67%; 33.33%) neutropenia (93.33%; 66.67%), decreased platelet rely (53.33%; 0%), elevated alkaline phosphatase (53.33%; 0%) and hypokalemia (40%; 13.33%). Notably, no deaths had been deemed therapy associated.
Reference:
“Tislelizumab (Tisle) mixed with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line therapy of superior gastric/gastroesophageal junction adenocarcinoma (AGC): OS evaluation outcomes of the SYLT-023” by Dr. Liyu Su et al., Journal of Medical Oncology.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
